TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report sent to investors on Monday, MarketBeat.com reports. They currently have a $10.00 price target on the stock. Wedbush also issued estimates for TScan Therapeutics’ FY2024 earnings at ($1.13) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($0.88) EPS and FY2028 earnings at $0.40 EPS.

Several other research firms have also recently weighed in on TCRX. HC Wainwright reiterated a buy rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 4th. Needham & Company LLC reaffirmed a buy rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Monday. Finally, BTIG Research began coverage on shares of TScan Therapeutics in a research report on Thursday, May 16th. They set a buy rating and a $12.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, TScan Therapeutics currently has a consensus rating of Buy and an average price target of $12.00.

TScan Therapeutics Price Performance

Shares of TScan Therapeutics stock opened at $5.79 on Monday. The stock has a market capitalization of $306.08 million, a P/E ratio of -4.52 and a beta of 0.83. TScan Therapeutics has a one year low of $1.97 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.23 and a quick ratio of 5.23. The business’s 50 day simple moving average is $6.76 and its two-hundred day simple moving average is $7.15.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. Analysts forecast that TScan Therapeutics will post -1.25 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TCRX. Pale Fire Capital SE increased its stake in TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after purchasing an additional 4,998 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of TScan Therapeutics in the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company purchased a new stake in shares of TScan Therapeutics during the second quarter valued at approximately $90,000. American Century Companies Inc. increased its position in shares of TScan Therapeutics by 48.9% during the second quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after acquiring an additional 15,596 shares in the last quarter. Finally, Cannon Global Investment Management LLC bought a new position in TScan Therapeutics in the 1st quarter valued at approximately $139,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.